AstraZeneca has received approval from the Japanese Ministry of Health for Saphnelo. The drug is intended to treat adult patients with systemic lupus erythematosus. Saphnelo is already approved in the U.S. for the treatment of moderate to severe SLE, and is under review in the EU.